Editor-in-Chief: Edward Meinert, MA (Oxon), MSc, MBA, MPA, PhD, CEng, FBCS, EUR ING
Edward Meinert, MA (Oxon), MSc, MBA, MPA, PhD, CEng, FBCS, EUR ING
JMIRx Med (ISSN 2563-6316) is an overlay journal to JMIR Preprints and MedRxiv, (other preprint servers are being onboarded). JMIRx peer-reviews preprints and publishes their revised "version of record" with peer-review reports across a broad range of medical, clinical and related health sciences. Unlike the majority of JMIR journals, papers published in this journal do not require a digital health focus - in fact, most papers we published in 2020 were related to COVID19, but we publish all research that qualifies for preprinting on MedRxiv.
Conceived to address the urgent need to make highly relevant scientific information available as early as possible without losing the quality of the peer-reviewed process, this innovative new journal is the first in a new series of “superjournals”. Superjournals (a type of "overlay" journal) sit on top of preprint servers (JMIRx-Med serves MedRxiv and JMIR Preprints), offering peer-review and everything else a traditional scholarly journal does. Our goal is to rapidly peer review and publish a paper. All JMIRx Med papers must have originated as a preprint.
All JMIRx Med papers are rigorously peer-reviewed, copyedited and XML-tagged. Accepted papers are published along with the related Peer Review Reports and Author Responses to Peer Review Reports, providing an additional layer of transparency to the scholarly publishing process.
There is currently no Article Processing Fee for this journal. We are selling institutional memberships to funders, libraries and library consortia under the name Plan P (Subscribe to Open Science).
To submit a preprint to JMIRx, either submit a Preprint directly to JMIRx (and opt-in when you are asked to expose the submission on JMIR Preprints) or upload a Preprint to MedRxiv and then user the M2J (or here called M2JMIR) functionality at MedRxiv to submit the paper to the Journal of Medical Internet Research - you will then receive an email with a link to the JMIR submission form, where you must change the target journal to JMIRx.
Approximately 80% of those infected with COVID-19 are immune. They are asymptomatic unknown carriers who can still infect those with whom they come into contact. Understanding what makes them immune could inform public health policies as to who needs to be protected and why, and possibly lead to a novel treatment for those who cannot, or will not, be vaccinated once a vaccine is available.
Preprints Open for Peer-Review
Open Peer Review Period:
Open Peer Review Period: